A phase 1 clinical trial of IDB003 for COVID-2019 infections
Latest Information Update: 20 Jul 2020
Price :
$35 *
At a glance
- Drugs IDB 003 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 20 Jul 2020 New trial record
- 15 Jul 2020 According to an IDBiologics media release, company plans to file an Investigational New Drug (IND) application to begin this trial in the third quarter of 2020.